International Expert Consensus Optimizes Asparaginase and Blinatumomab in Frontline ALL

This international consensus addresses how to integrate asparaginase with the now-standard frontline blinatumomab backbone, including dosing, therapeutic drug monitoring, and adaptations for resource-limited settings.

International Expert Consensus on Asparaginase and BlinatumomabAmerican Cancer Society (Cancer journal)acute lymphoblastic leukemiaasparaginaseblinatumomabantimetabolites Oncology / Supportive Care

Background Information

Expert consensus guides asparaginase and blinatumomab integration in leukemia treatment.

Asparaginase and blinatumomab therapies are central to frontline acute lymphoblastic leukemia treatments, requiring optimized protocols for safety and efficacy. An expert panel reached consensus on dosing, hypersensitivity management, and integration strategies for asparaginase, especially in combination with blinatumomab. Guidelines help optimize acute lymphoblastic leukemia treatment across various healthcare settings, considering resource limitations and drug interactions. Expert consensus offers practical guidance on integrating asparaginase and blinatumomab in acute lymphoblastic leukemia therapy.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: DeAngelo DJ, Avagyan A, Alfaro J, Conter V, de Martino Lee ML, Hutnik Ł, Hwang M, Inaba H, Manabe A, Park JH, Pieters R, Rizzari C, Saha V, Teachey DT, van der Sluis IM, Howard SC

Citation: DeAngelo DJ, Avagyan A, Alfaro J, et al. Optimizing safety and efficacy of asparaginase and blinatumomab therapy in frontline acute lymphoblastic leukemia regimens in diverse health care settings-international expert consensus. Cancer. 2026;132(16):e70559. doi:10.1002/cncr.70559

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →